- Home
- BRNS vs VYNE Comparison
BRNS vs VYNE Comparison
Compare BRNS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- VYNE
- Stock Information
- Founded
- BRNS 2016
- VYNE 2003
- Country
- BRNS United Kingdom
- VYNE United States
- Employees
- BRNS N/A
- VYNE N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- VYNE Health Care
- Exchange
- BRNS Nasdaq
- VYNE Nasdaq
- Market Cap
- BRNS 38.7M
- VYNE 35.7M
- IPO Year
- BRNS 2021
- VYNE 2018
- Fundamental
- Price
- BRNS $0.87
- VYNE $1.25
- Analyst Decision
- BRNS Strong Buy
- VYNE Strong Buy
- Analyst Count
- BRNS 2
- VYNE 2
- Target Price
- BRNS $3.00
- VYNE $6.25
- AVG Volume (30 Days)
- BRNS 33.3K
- VYNE 224.9K
- Earning Date
- BRNS 05-07-2025
- VYNE 05-08-2025
- Dividend Yield
- BRNS N/A
- VYNE N/A
- EPS Growth
- BRNS N/A
- VYNE N/A
- EPS
- BRNS N/A
- VYNE N/A
- Revenue
- BRNS $14,969,000.00
- VYNE $605,000.00
- Revenue This Year
- BRNS N/A
- VYNE N/A
- Revenue Next Year
- BRNS N/A
- VYNE N/A
- P/E Ratio
- BRNS N/A
- VYNE N/A
- Revenue Growth
- BRNS 4381.74
- VYNE 43.03
- 52 Week Low
- BRNS $0.64
- VYNE $1.27
- 52 Week High
- BRNS $2.45
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- BRNS 47.94
- VYNE 34.91
- Support Level
- BRNS $0.80
- VYNE $1.18
- Resistance Level
- BRNS $0.95
- VYNE $1.33
- Average True Range (ATR)
- BRNS 0.12
- VYNE 0.10
- MACD
- BRNS -0.00
- VYNE -0.01
- Stochastic Oscillator
- BRNS 29.70
- VYNE 19.44
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.